Our findings demonstrate the SphK2/CERT axis as a novel therapeutic target for NAFLD-HCC, although the intricate role of these coupled lipid regulators in different cancer contexts warrants further investigation. This evidence concerns the gene SPHK2 and hepatocellular carcinoma.